While primary care clinicians play a crucial role in the care of patients with CKD, a holistic approach to care with multidisciplinary team involvement is essential.

Late identification of CKD in patients with T2D can lead to higher economic costs and increased risks of adverse events.

The current healthcare system values high procedural volumes over value-based care, which can impede on the management of chronic conditions like CKD and T2D.

An initiative in the Indian Health Service can serve as an example of how a systematic population-based approach can implemented for patients with CKD and T2D.

This is episode 6 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.

Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA), Radica Alicic (Internist and Clinical Professor at the University of Washington), and Nihar R. Desai (Cardiologist and Associate Professor of Medicine at Yale University) emphasize the key role of primary care clinicians in CKD management while highlighting the need for a multidisciplinary, holistic approach, as delayed CKD detection in T2D patients increases costs and risks.

Patient education and activation is important in early disease management, and includes self-care, monitoring, and adherence to treatment plans.

Patient support groups and resources are available for patients with CKD associated with T2D.

Early management of CKD associated with T2D offers numerous advantages.

This is episode 5 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.

Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA) and Jay H. Shubrook (Primary Care Physician/Diabetologist and Professor in the Primary Care Department at Touro University of California) discuss the importance of patient education and activation in early disease management and highlight the role of support groups and resources

American Diabetes Association (ADA) and Kidney Disease Improving Global Outcomes (KDIGO) emphasize the importance of comprehensive, patient-centered medical care for improved outcomes in patients.

Nonpharmaceutical strategies, such as lifestyle modifications, play a critical role in managing CKD associated with T2D.

ADA guidelines recommend diabetes self-management education and support (DSMES) for all individuals with diabetes.

Primary care clinicians play a critical role in the early identification and management of CKD and collaborative effort is needed to improve care of these patients.

This is episode 4 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.

Drs. Radica Alicic (Internist and Clinical Professor at the University of Washington) and Jennifer B. Green (Endocrinologist and Professor of Medicine at Duke University Medical Center) emphasize the importance of patient-centered care, nonpharmaceutical strategies, and primary care clinicians' role in early CKD management, stressing collaboration to improve outcomes in T2D patients.

The complications of CKD affect all organ systems, and there are overlapping risk factors associated with CKD progression and increased CV risk.

Heart failure can affect the development and progression of CKD and contributes to morbidity and mortality in patients with CKD and ESKD.

Reduced eGFR is associated with increased risk of CV mortality and HF hospitalization, and elevated UACR is also predictive of HF outcomes.

As CKD progresses, it can cause increased costs to the healthcare system. There is additional increase in expenditure when patients also have cardiovascular disease.

This is episode 3 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.

Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA) and Andrew James Sauer (Cardiologist and cardiovascular researcher at Saint Luke’s Hospital and Mid America Heart Institute of Kansas City) explore the shared risk factors for CKD progression and cardiovascular disease, including heart failure, reduced eGFR, and elevated UACR, which increase morbidity, mortality, and healthcare costs in patients with CKD associated with T2D.

The KDIGO heatmap is a useful tool for staging CKD, assessing risk of CKD progression, and initiating conversations on potential interventions.

ADA, KDIGO, and AACE recommend both eGFR and albuminuria screening at least annually in all patients with T2D.

The preferred test for albuminuria is UACR.

CKD testing in patients with diabetes is underutilized, particularly UACR testing.

This episode 2 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.

Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA) and Radica Alicic (Internist and Clinical Professor at the University of Washington) highlight the KDIGO heatmap as a key tool for CKD staging and assessing progression risk and guidelines that recommend annual eGFR and albuminuria screening, as CKD testing remains underutilized in T2D patients.

CKD diagnosis relies on routine screening as early-stage CKD is often asymptomatic.

Risk of developing kidney disease differs among individuals, with race, ethnicity, and socioeconomic disadvantages being risk factors.

Majority of patients with CKD will die from cardiovascular disease before reaching ESKD.

Early detection and appropriate intervention of CKD associated with T2D has the potential to slow CKD progression and improve patient outcomes.

This is episode 1 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.

Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA) and Radica Alicic (Internist and Clinical Professor at the University of Washington) provide an overview of CKD diagnosis, risk factors, patient impact, and strategies to slow progression and improve outcomes in patients with T2D.